

August 31, 2017

## Acme Generics LLP

### Summary of rated instruments

Instrument*	Rated Amount (in Rs. crore)	Rating Action
Term Loan	75.0	[ICRA]BBB (SO) (stable) reaffirmed
Cash Credit Facilities	10.0	[ICRA]BBB (SO) (stable) reaffirmed

\*Instrument details are provided in Annexure-1

### Rating action

ICRA has reaffirmed a long-term rating of [ICRA]BBB (SO) (pronounced as ICRA triple B Structured Obligation) for the Rs. 85.0 crore<sup>1</sup> bank facilities of Acme Generics LLP (Acme Generics)<sup>2</sup>. The outlook on the long term rating is Stable. The letters SO in parenthesis suffixed to a rating symbol stands for Structured Obligation. An SO rating is specific to the rated issue, its terms, and its structure. SO ratings do not represent ICRA's opinion on the general credit quality of the issuers concerned.

### Rationale

ICRA's rating for Acme Generics is based on the unconditional and irrevocable corporate guarantee extended by Acme Formulation Private Limited (Acme Formulation) to the entire bank facilities of Acme Generics, for the timely payment of the principal along with accrued interest on the due payment dates<sup>3</sup>.

In arriving at the ratings for Acme Formulation, ICRA has factored in its strong business linkages with Acme Generics besides the common management shared by the entities. Acme Generics was set up to maintain continuity of business for the Acme Group as the excise and income tax exemption available for Acme Formulation's manufacturing facility ended on March 31, 2015. Thus, a majority of business of Acme Formulation was gradually shifted to Acme Generics on commencement of commercial operations of the latter's plant in December 2015. The two entities have been collectively referred to as the Acme Group.

The rating reaffirmation factors in the stable operational profile of the Acme Group, which is an established contract manufacturer for leading pharmaceutical companies in India. The Group continues to have a strong customer profile comprising clients such as Abbott India Limited and Cadilla Healthcare Limited, among others. However, despite efforts to penetrate the multi-national pharmaceutical companies operating in India, the company remains largely a supplier to the generic business of domestic pharmaceutical companies. A delay in commercialisation of the facility of Acme Generics, in conjunction with the expiry of excise exemption benefits for Acme Formulation's facility, led to loss of business for the Group in FY2016. Consequently, the scale of operations of the Group had declined by ~25%. In FY2017, however, buoyed by a ramp up in scale of operations of the manufacturing facility of Acme Generics, the Group's revenues reported a healthy growth in revenues and expansion in operating profits. The Group's established relationships with various customers, coupled with the availability of abundant idle capacity, augurs well for revenue growth over the medium term.

<sup>1</sup> 100 lakh = 1 crore = 10 million

<sup>2</sup> For complete rating scale and definitions, please refer to ICRA's website [www.icra.in](http://www.icra.in) or other ICRA Rating Publications.

<sup>3</sup> The rated instrument does not involve a structured payment mechanism.

The ratings also take into account the comfortable financial risk profile of the company, characterised by healthy cash accruals and a strong liquidity profile. At a standalone level, while a reduced scale of operations has led to lower operating profits, the debt coverage indicators continue to remain healthy. At a group level, while the return indicators have moderated from the earlier healthy levels as a result of significant investments undertaken to setup to Acme Generics facility, they continue to remain at moderate to healthy levels. Apart from its investment in Acme Generics, Acme Formulation continues to have significant investments in other group companies as well, and has also extended corporate guarantees for facilities availed by other companies in the group. Any incremental support to these entities, going forward, could result in deterioration of the financial risk profile and would remain a key rating sensitivity.

ICRA notes the fact that the implementation of Goods and Services Tax (GST) has led to a change in the overall tax and duty structure in the pharmaceutical industry, with benefits available in excise/tax free zones for contract manufacturers being substantially diluted. While the established relationships of the Acme Group in the domestic market, coupled with the management's increased focus on gaining incremental business in the exports market, remain a positive rating factor, the impact of the dilution in excise exemption benefits on the business prospects of the Group would continue to be monitored.

### Key rating drivers

#### Credit strengths

- **Established track record as a leading contract manufacturer for major pharmaceutical companies** – The Acme Group is engaged in providing contract manufacturing services to the pharmaceutical industry. The group's client base comprises leading pharmaceutical players and its client base is fairly diversified, with its top five customers contributing ~53% to the company's revenues in FY2017.
- **Part of a well-diversified JCBL Group, which has a presence across multiple industries** – The JCBL Group is a conglomerate of companies with varied interests in automobiles, pharmaceuticals, design, information technology and international trading. While Acme Formulation is the leading company of the Group in the pharmaceutical sector, JCBL Limited, a manufacturer of bodies for buses and special vehicles, is the flagship company of the Group in the automobile sector.
- **Abundant capacity available post commercialisation of Acme Generics facility provides opportunities for growth** - The excise and income tax benefits for Acme Formulation's facility ended on March 31, 2015. For continuing to benefit excise exemption benefits, the promoters set up another manufacturing facility (under the partnership firm, Acme Generics), which commenced operations from December 2015. A majority of products manufactured at Acme Formulation were gradually shifted to the new facility, which continues to enjoy excise exemption benefits. The presence of abundant capacity, post the setting up of the Acme Generics facility, provides healthy growth opportunities for the Group, going forward.

#### Credit weaknesses

- **Excise exemption benefits available to unit of Acme Generics have been muted post implementation of GST** – The implementation of GST has led to a change in the overall tax and duty structure in the pharmaceutical industry, and has diluted the benefits available in excise/tax free zones substantially. While the contract manufacturing industry association is in discussions with the Government for compensation related to the dilution of excise exemption benefits available earlier, the impact of the same on the business prospects of the Acme Group remains to be seen.

- **Primarily a supplier for the generic business of domestic pharmaceutical companies; exports remain modest** – The group remains primarily a supplier of generics drugs to domestic pharmaceuticals companies, with its development and manufacturing capabilities covering solid and semi-solid dosage forms across antibiotics, analgesics, anti-fungal, cough and cold preparations, cardiovascular, hormonal products, etc. The management's focus on exports had remained modest so far, with marginal exports being undertaken in semi-regulated markets. However, following the setting up of a new unit for the domestic market, the management is focused on increasing the contribution of the exports segment to overall revenues, going forward.
- **Significant investments and loans extended to group companies, which have yet to scale up operations** – Apart from its investment in Acme Generics, Acme Formulation also has substantial investments in another group company, Immacule Lifesciences Private Limited, an entity engaged in contract manufacturing of liquid orals with a focus on export markets. While the facility commenced commercial operations from December 2014, it is yet to scale up its operations, with the facility and drugs approval processes entailing a long gestation period. Till the facility's scale of operations improves, Acme Formulation could be required to fund the operational losses recorded.

**Analytical approach:** For arriving at the ratings, ICRA has applied its rating methodologies as indicated below:

**Links to applicable criteria:**

**Corporate Credit Rating Methodology**

**Rating Methodology for Pharmaceutical Industry**

**About the company:**

Acme Generics, a partnership firm established in 2014, is engaged in providing contract dosage for development and manufacturing services to the pharmaceutical industry. Acme Formulation, an established pharmaceutical contract manufacturer, holds a majority stake in the firm (81% through direct and indirect holdings).

The company's manufacturing facility is in Baddi (Himachal Pradesh). The firm's development and manufacturing capabilities cover prescription products in solid and semi-solid dosage forms. Being located in Baddi, the facility is eligible for 100% outright excise duty exemption for a period of 10 years from the date of commencement of commercial production, 100% income tax exemption for an initial period of five years and thereafter 30% for a further period of five years. The excise and income tax benefits end on March 31, 2020.

**About the guarantor:**

Acme Formulation is engaged in providing contract dosage for development and manufacturing services to the pharmaceutical industry. The company is a part of the JCBL Group, which has a diversified presence across automobiles, pharmaceuticals, information technology and international trading industries.

It has a manufacturing facility located in Nalagarh, Solan (Himachal Pradesh). Its development and manufacturing capabilities cover prescription products in solid and semi-solid dosage forms. Its manufacturing facility, setup in 2003, is engaged in manufacturing tablets and capsules. The facility was eligible for 100% outright excise duty exemption for a period of 10 years from the date of commencement of commercial production, 100% income tax exemption for an initial period of five years and thereafter 30% for a further period of five years. The excise and income tax benefits exemption for the facility ended on March 31, 2015.

## Key Financial Indicators

Indicator	FY2016	FY2017*
Operating Income (Rs. crore)	33.4	204.8
PAT ( Rs. crore )	-7.4	12.7
OBDITA/OI (%)	-5.7%	13.9%
ROCE (%)	-6.8%	17.1%
Total Debt/ TNW (times)	2.1	1.6
Total Debt/ OPBDIT (times)	-43.8	2.9
Interest coverage (times)	-0.7	3.1
NWC/ OI (%)	6.9%	5.5%

*OI: Operating Income; PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation; ROCE: PBIT/Avg (Total Debt + Tangible Net-Worth + Deferred Tax Liability - Capital Work - in Progress);*

*NWC: Net Working Capital; \*Provisional Financials*

**Status of non-cooperation with previous CRA:** In its rationale published on Acme Generics, dated July 18, 2017, Crisil Ratings has stated the following:

“CRISIL has been consistently following up with ACME Generics LLP (ACME) for obtaining information through letters and emails dated January 19, 2017 and February 09, 2017 among others, apart from telephonic communication. However, the issuer has remained non cooperative.

The investors, lenders and all other market participants should exercise due caution while using the rating assigned/reviewed with the suffix 'ISSUER NOT COOPERATING'. These ratings lack a forward looking component as it is arrived at without any management interaction and is based on best available or limited or dated information on the company.

Despite repeated attempts to engage with the management, CRISIL failed to receive any information on either the financial performance or strategic intent of ACME Generics LLP. This restricts CRISIL's ability to take a forward looking view on the credit quality of the entity. CRISIL believes that the information available for ACME Generics LLP is consistent with 'Scenario 1' outlined in the 'Framework for Assessing Consistency of Information with CRISIL B' Rating category or lower. Based on the last available information, CRISIL has downgraded the rating at 'CRISIL B+/Stable’.

**Any other information:** Not applicable

**Rating history for last three years:**
**Table:**

S. No	Instrument	Current Rating (FY2018)			Chronology of Rating History for the past 3 years			
		Type	Amount Rated (Rs. crore)	Date & Rating	Date & Rating in FY2017	Date & Rating in FY2016	Date & Rating in FY2015	
				<b>August 2017</b>	<b>August 2016</b>	-	-	
1	Term Loan	Long Term	75.0	[ICRA]BBB (SO) (stable)	[ICRA]BBB (SO) (stable)	-	-	
2	Cash Credit Facilities	Long Term	10.0	[ICRA]BBB (SO) (stable)	[ICRA]BBB (SO) (stable)	-	-	

**Complexity level of the rated instrument:**

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website [www.icra.in](http://www.icra.in)

**Annexure-1**  
**Instrument Details**

<b>Instrument</b>	<b>Date of Issuance / Sanction</b>	<b>Coupon Rate</b>	<b>Maturity Date</b>	<b>Amount Rated (Rs. crore)</b>	<b>Current Rating and Outlook</b>
Term Loan - 1	March 2015	-	March 2025	50.0	[ICRA]BBB (SO) (stable)
Term Loan – 2	March 2015	-	March 2025	25.0	[ICRA]BBB (SO) (stable)
Cash Credit Facilities	-	-	-	10.0	[ICRA]BBB (SO) (stable)

Source: Acme Generics

## Contact Details

### Analyst Contacts

**Subrata Ray**  
+91 22 2433 1086  
[subrata@icraindia.com](mailto:subrata@icraindia.com)

**Anupama Arora**  
+91 124 4545 303  
[anupama@icraindia.com](mailto:anupama@icraindia.com)

**Rohan Kanwar Gupta**  
+91 124 4545 808  
[rohan.kanwar@icraindia.com](mailto:rohan.kanwar@icraindia.com)

### Relationship Contact

**Jayanta Chatterjee**  
+91 80 4332 6401  
[jayantac@icraindia.com](mailto:jayantac@icraindia.com)

### About ICRA Limited:

**ICRA Limited** was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

© Copyright, 2017, ICRA Limited. All Rights Reserved  
Contents may be used freely with due acknowledgement to ICRA

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.

**Registered Office****ICRA Limited**

1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi 110001  
Tel: +91-11-23357940-50, Fax: +91-11-23357014

**Corporate Office****Mr. Vivek Mathur**

Mobile: +91 9871221122

Email: [vivek@icraindia.com](mailto:vivek@icraindia.com)

Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002  
Ph: +91-124-4545310 (D), 4545300 / 4545800 (B) Fax; +91- 124-4050424

**Mumbai****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

3rd Floor, Electric Mansion  
Appasaheb Marathe Marg, Prabhadevi  
Mumbai—400025,  
Board : +91-22-61796300; Fax: +91-22-24331390

**Kolkata****Mr. Jayanta Roy**

Mobile: +91 9903394664

Email: [jayanta@icraindia.com](mailto:jayanta@icraindia.com)

A-10 & 11, 3rd Floor, FMC Fortuna  
234/3A, A.J.C. Bose Road  
Kolkata—700020  
Tel +91-33-22876617/8839 22800008/22831411,  
Fax +91-33-22870728

**Chennai****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

5th Floor, Karumuttu Centre  
634 Anna Salai, Nandanam  
Chennai—600035  
Tel: +91-44-45964300; Fax: +91-44 24343663

**Bangalore****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

'The Millenia'  
Tower B, Unit No. 1004, 10th Floor, Level 2 12-14, 1 & 2,  
Murphy Road, Bangalore 560 008  
Tel: +91-80-43326400; Fax: +91-80-43326409

**Ahmedabad****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

907 & 908 Sakar -II, Ellisbridge,  
Ahmedabad- 380006  
Tel: +91-79-26585049, 26585494, 26584924; Fax:  
+91-79-25569231

**Pune****Mr. L. Shivakumar**

Mobile: +91 9821086490

Email: [shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

5A, 5th Floor, Symphony, S.No. 210, CTS 3202, Range  
Hills Road, Shivajinagar, Pune-411 020  
Tel: + 91-20-25561194-25560196; Fax: +91-20-  
25561231

**Hyderabad****Mr. Jayanta Chatterjee**

Mobile: +91 9845022459

Email: [jayantac@icraindia.com](mailto:jayantac@icraindia.com)

4th Floor, Shobhan, 6-3-927/A&B. Somajiguda, Raj  
Bhavan Road, Hyderabad—500083  
Tel:- +91-40-40676500